Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
On Tuesday, Celldex Therapeutics, Inc. (NASDAQ:CLDX) released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback